TotalMarketCap

Avalo Therapeutics

AVTXNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$355.567 M

$6.63 -6.22%

Close of 6 Nov 2026

As of 6 Nov 2026, Avalo Therapeutics (AVTX) has a market capitalization of $355.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$59.0K

#3584 by revenue

Earnings

-$78.3M

Loss-making

Shares outstanding

57,823,083

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #209AltimmuneALT$382.2M
  2. #210Lyell ImmunopharmaLYEL$360.9M
  3. #211Avalo TherapeuticsAVTX$355.6M
  4. #212RezoluteRZLT$354.5M
  5. #213Contineum TherapeuticsCTNM$353.2M

What if Avalo Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$526,512.77

Per share 79,414× higher

Bitcoin $1.53T

$28,488.69

Per share 4,297× higher

Apple $5.02T

$93,525.71

Per share 14,106× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Avalo Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.